The Therapeutic Trip of Melatonin Eye Drops: From the Ocular Surface to the Retina

被引:6
作者
Rusciano, Dario [1 ]
Russo, Cristina [2 ]
机构
[1] Univ Catania, Fidia Res Ctr, Via Santa Sofia 89, I-95123 Catania, Italy
[2] Univ Catania, Dept Biomed & Biotechnol Sci, Via Santa Sofia 89, I-95123 Catania, Italy
基金
英国科研创新办公室;
关键词
melatonin; drug delivery; nanotech formulation; glaucoma; dry eye; cataract; diabetic retinopathy; macular degeneration; uveitis; myopia; INTRAOCULAR-PRESSURE; EXPERIMENTAL UVEITIS; RECEPTOR EXPRESSION; SIGNAL-TRANSDUCTION; CATARACT FORMATION; OXIDATIVE STRESS; CIRCADIAN-RHYTHM; PINEAL-GLAND; GLAUCOMA; LENS;
D O I
10.3390/ph17040441
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Melatonin is a ubiquitous molecule found in living organisms, ranging from bacteria to plants and mammals. It possesses various properties, partly due to its robust antioxidant nature and partly owed to its specific interaction with melatonin receptors present in almost all tissues. Melatonin regulates different physiological functions and contributes to the homeostasis of the entire organism. In the human eye, a small amount of melatonin is also present, produced by cells in the anterior segment and the posterior pole, including the retina. In the eye, melatonin may provide antioxidant protection along with regulating physiological functions of ocular tissues, including intraocular pressure (IOP). Therefore, it is conceivable that the exogenous topical administration of sufficiently high amounts of melatonin to the eye could be beneficial in several instances: for the treatment of eye pathologies like glaucoma, due to the IOP-lowering and neuroprotection effects of melatonin; for the prevention of other dysfunctions, such as dry eye and refractive defects (cataract and myopia) mainly due to its antioxidant properties; for diabetic retinopathy due to its metabolic influence and neuroprotective effects; for macular degeneration due to the antioxidant and neuroprotective properties; and for uveitis, mostly owing to anti-inflammatory and immunomodulatory properties. This paper reviews the scientific evidence supporting the use of melatonin in different ocular districts. Moreover, it provides data suggesting that the topical administration of melatonin as eye drops is a real possibility, utilizing nanotechnological formulations that could improve its solubility and permeation through the eye. This way, its distribution and concentration in different ocular tissues may support its pleiotropic therapeutic effects.
引用
收藏
页数:27
相关论文
共 50 条
  • [21] From Gut to Eye: Exploring the Role of Microbiome Imbalance in Ocular Diseases
    Tirziu, Andreea-Talida
    Susan, Monica
    Susan, Razvan
    Sonia, Tanasescu
    Harich, Octavia Oana
    Tudora, Adelina
    Varga, Norberth-Istvan
    Tiberiu-Liviu, Dragomir
    Avram, Cecilia Roberta
    Boru, Casiana
    Munteanu, Mihnea
    Horhat, Florin George
    JOURNAL OF CLINICAL MEDICINE, 2024, 13 (18)
  • [22] Perspectives in Therapeutic Innovation in Ocular Surface Disorders and Dry Eye Syndrome
    Cade-Jorge, Fabiano
    Jorge, Italo Cade
    Kusabara, Alessandra A.
    Rocha, Eduardo M.
    RECENT PATENTS ON ENDOCRINE METABOLIC & IMMUNE DRUG DISCOVERY, 2009, 3 (03) : 194 - 199
  • [23] Angiotensin Receptor Blockers in cyclodextrin nanoparticle eye drops: Ocular pharmacokinetics and pharmacologic effect on intraocular pressure
    Lorenzo-Soler, Laura
    Olafsdottir, Olof Birna
    Garhoefer, Gerhard
    Jansook, Phatsawee
    Kristinsdottir, Iris Myrdal
    Tan, Aimin
    Loftsson, Thorsteinn
    Stefansson, Einar
    ACTA OPHTHALMOLOGICA, 2021, 99 (04) : 376 - 382
  • [24] Relationship between OSDI score and biomicroscopic ocular surface damages in glaucomatous patients treated with preserved antiglaucomatous eye drops
    Lajmi, H.
    Chelly, Z.
    Choura, R.
    Mansour, K. B.
    Hmaied, W.
    JOURNAL FRANCAIS D OPHTALMOLOGIE, 2021, 44 (09): : 1326 - 1331
  • [25] Serum eye drops for the treatment of ocular surface diseases: a systematic review and meta-analysis
    Franchini, Massimo
    Cruciani, Mario
    Mengoli, Carlo
    Marano, Giuseppe
    Capuzzo, Enrico
    Pati, Ilaria
    Masiello, Francesca
    Veropalumbo, Eva
    Pupella, Simonetta
    Vaglio, Stefania
    Liumbruno, Giancarlo M.
    BLOOD TRANSFUSION, 2019, 17 (03) : 200 - 209
  • [26] Ocular surface response of two preservative-free cylcosporine A emulsion eye drops in a mouse model of dry eye
    Daull, Philippe
    Nagano, Takashi
    Gros, Emilie
    Feraille, Laurence
    Barabino, Stefano
    Garrigue, Jean-Sebastien
    CURRENT EYE RESEARCH, 2021, 46 (08) : 1096 - 1104
  • [27] Meta analysis about the efficacy and safety of anti-ocular hypertension eye drops without benzalkonium chloride
    Wang, Yan-Qing
    Wang, Xin
    Liu, Ping
    ASIAN PACIFIC JOURNAL OF TROPICAL MEDICINE, 2013, 6 (12) : 1004 - 1008
  • [28] Ocular Redness Measured with the Keratograph 5M in Patients Using Anti-Glaucoma Eye Drops
    Perez Bartolorne, Francisco
    Martinez de la Casa, Jose Maria
    Arriola Villalobos, Pedro
    Fernandez Perez, Cristina
    Polo, Vicente
    Sanchez Jean, Ruben
    Garcia Feijoo, Julian
    SEMINARS IN OPHTHALMOLOGY, 2018, 33 (05) : 643 - 650
  • [29] Autophagy in dry eye disease: Therapeutic implications of autophagy modulators on the ocular surface
    Jeyabalan, Nallathambi
    Pillai, Aswathi M.
    Khamar, Pooja
    Shetty, Rohit
    Mohan, Rajiv R.
    Ghosh, Arkasubhra
    INDIAN JOURNAL OF OPHTHALMOLOGY, 2023, 71 (04) : 1285 - 1291
  • [30] Clinical Trials of Therapeutic Ocular Surface Medium for Moderate to Severe Dry Eye
    Watson, Stephanie L.
    Daniels, Julie T.
    Geerling, Gerd
    Dart, John K. G.
    CORNEA, 2010, 29 (11) : 1241 - 1246